Lyell Immunopharma Announces Board and Executive Changes
Ticker: LYEL · Form: 8-K · Filed: Jun 9, 2025 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | Jun 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-changes
Related Tickers: LYEL
TL;DR
Lyell Immunopharma (LYEL) filed an 8-K detailing board shakeups and executive comp changes.
AI Summary
Lyell Immunopharma, Inc. announced on June 9, 2025, changes in its board and executive compensation. The filing details the departure of directors, election of new directors, and appointments of certain officers, along with updates to their compensatory arrangements.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook.
Risk Assessment
Risk Level: low — This filing reports routine corporate governance changes and does not appear to involve significant financial transactions or operational disruptions.
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- June 9, 2025 (date) — Date of earliest event reported
- 201 Haskins Way, South San Francisco, CA 94080 (location) — Principal Executive Offices
FAQ
What specific items are covered in this 8-K filing by Lyell Immunopharma, Inc.?
This 8-K filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 9, 2025.
What is the exact name of the Registrant as specified in its charter?
The exact name of the Registrant is Lyell Immunopharma, Inc.
In which state was Lyell Immunopharma, Inc. incorporated?
Lyell Immunopharma, Inc. was incorporated in Delaware.
What is the business address of Lyell Immunopharma, Inc.?
The business address of Lyell Immunopharma, Inc. is 201 Haskins Way, South San Francisco, California, 94080.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding Lyell Immunopharma, Inc. (LYEL).